The Emerging Drug Targets Outlook: An Analysis of Novel Molecular Targets to Develop Innovative New Therapeutics
Posted on: Monday, 21 November 2005, 09:00 CST
Research and Markets (http://www.researchandmarkets.com/reports/c28127) has announced the addition of The Emerging Drug Targets Outlook: An Analysis of Novel Molecular Targets to Develop Innovative New Therapeutics to their offering.
Drug targets are generally proteins. Nucleic acids are possible drug targets, and approaches such as RNA interference (RNAi) may indeed have advantages over proteins, but they have not so far been developed extensively. Protein targets consist mainly of enzymes, regulatory molecules such as cytokines, receptors for hormones or other regulatory molecules, transporters, and ion channels. Proteins that interact with small molecules are considered the most promising targets, because it is often possible to design or discover small molecule activators or inhibitors based on the natural ligands. Such substances are relatively straightforward to develop as drugs.
Overall, enzyme targets account for over 50% of marketed drugs, and GPCR targets represent more than 20%, including 23 of the 100 best-selling drugs in the US. Hence the other target classes between them make up the remaining 25-30% of marketed drugs. Aberrant signal transduction plays a key part in the pathology of many serious diseases including cancer, inflammatory, cardiovascular, metabolic, and neuropsychiatric diseases. Proteins involved in signal transduction pathways therefore represent important drug targets. Three prominent superfamilies of proteins involved in signal transduction are: GPCRs, protein kinases, and nuclear receptors.
Topics covered in the report include:
-- The drug target landscape
-- Drug target selection
-- GPCRs
-- Protein kinases
-- Nuclear receptors
-- Implications for drug discovery
Case studies include:
-- Argenta Discovery
-- Biogen Idec
-- Inpharmatica
For more information visit http://www.researchandmarkets.com/reports/c28127
Source: Business Wire
Related Articles
- North Carolina Based Cromoz Inc. Launches Carbon Nanotechnology for Target Drug Delivery System in Cancer Treatment in Hyderabad, India
- ZyStor Therapeutics, Inc. Cleared to Begin Clinical Trial for Targeted Protein Therapeutic for the Treatment of Pompe Disease
- CeNeRx BioPharma Awarded New Patent for its Innovative Compounds That Selectively Target Peripheral Cannabinoid Receptors
- Xanthus' Xanafide Bypasses Multi-Drug Resistance Proteins in Acute Myeloid Leukemia
- Abbott Researchers Target Neuronal Nicotinic Receptors for Treatment of Pain and Cognition
- Oncology Drug Development Update - Targeting the Epidermal Growth Factor Receptor (EGFr) Signal Transduction Pathway
- Idera Pharmaceuticals Announces the Granting of Patents on Immune Modulatory Compounds That Target Toll-Like Receptors
- MultiCell Enters into a Joint Venture With Living Cell Technologies to Develop Adult Liver Cell Technologies for Drug Discovery, Protein Production and Therapeutic Clinical Applications
- Moffitt-USF Head Toward First Human Trials of Anti-cancer Drug that Targets Protein AKT
- Arabidopsis RADICAL-INDUCED CELL DEATH1 Belongs to the WWE Protein- Protein Interaction Domain Protein Family and Modulates Abscisic Acid, Ethylene, and Methyl Jasmonate Responses
 |
 |
User Comments (0)
RSS Feeds